A benefit-risk assessment of benzbromarone in the treatment of gout: Was its withdrawal from the market in the best interest of patients?

Drug Safety

Volumn 31, Issue 8, 2008, Pages 643-665

  Lee, Ming Han H ^a   Graham, Garry G ^a   Williams, Kenneth M ^a   Day, Richard O ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Benefit risk assessment; Benzbromarone, adverse reactions; Benzbromarone, therapeutic use; Gout; Regulatory process

Indexed keywords

ACETYLSALICYLIC ACID; ALLO COMP; ALLOBENZ; ALLOPURINOL; ALLOPURINOL PLUS BENZBROMARONE; AZUBROMARON; BENZBROMARONE; COLCHICINE; COMBURIC; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 2C9; DUOVITAN; FACILIT; FEBUXOSTAT; GICHTEX PLUS; HAROLAN; HARPAGIN; INDOMETACIN; MAX URIC; METHOTREXATE; METHYLDOPA; MINURIC; NARCARICINA; NONSTEROID ANTIINFLAMMATORY AGENT; OBARON; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PARACETAMOL; PHENYLBUTAZONE; PHENYTOIN; PROBENECID; SULFINPYRAZONE; THROMBOXANE A2; URICOVAC COMP; URIFUGAN; UROPLUS; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC CONJUNCTIVITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DOSE KIDNEY FUNCTION RELATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; DRUG WITHDRAWAL; GASTROINTESTINAL IRRITATION; GENETIC RISK; GOUT; HUMAN; IMPOTENCE; JAUNDICE; KIDNEY DYSFUNCTION; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; NEPHROLITHIASIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

ANIMALS; BENZBROMARONE; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; GOUT; HUMANS; LIVER DISEASES; RISK FACTORS; URICOSURIC AGENTS;

EID: 47649130363     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831080-00002     Document Type: Review

References (122)

1. Sternon J, Kocheleff P, Couturier E, et al. Hypouricemizing effect of benzbromarone: study of 24 cases (preliminary results) [in French]. Acta Clin Belg 1967; 22 (5): 285-93
2. Nivet M, Marcovici J, Compagnon P, et al. The hypo-uricemic action of oral benziodarone [in French]. Sem Hop 1967 Jan 8; 43 (2): 135-8
3. Bekaert J, Deltour G, Broekhuysen J. Research on the benzofuran series III: study of the thyroid function in man during the administration of an iodized bensofuran derivative (Benziodarone) [in German]. Arch Int Pharmacodyn Ther 1961 Jul 1; 132: 339-48
4. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002 May 23; 417 (6887): 447-52
5. Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof. European patent EP1767531 [online]. Available from URL: http://www.freepatentsonline.com/EP1767531.html [Accessed 2008 May 19]
6. Maurer H, Wollenberg P. Urinary metabolites of benzbromarone in man. Arzneimittelforschung 1990 Apr; 40 (4): 460-2
7. de Vries JX, Walter-Sack I, Ittensohn A, et al. Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite. Clin Investig 1993 Nov; 71 (11): 947-52
8. McDonald MG, Rettie AE. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 2007 Dec; 20 (12): 1833-42
9. van der Klauw MM, Houtman PM, Stricker BH, et al. Hepatic injury caused by benzbromarone. J Hepatol 1994 Mar; 20 (3): 376-9
10. Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with benzbromarone [letter]. J Hepatol 2000 May; 32 (5): 874
11. Suzuki T, Suzuki T, Kimura M, et al. A case of fulminant hepatitis, possibly caused by benzbromarone [in Japanese]. Nippon Shokakibyo Gakkai Zasshi 2001 Apr; 98 (4): 421-5
12. Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002 May; 17 (5): 625-6
13. Jansen TL, Reinders MK, van Roon EN, et al. Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"? [letter]. Clin Exp Rheumatol 2004 Sep-Oct; 22 (5): 651
14. Thomson Healthcare. Benzbromarone. In: Martindale: the complete drug reference (internet database) [online]. Available from URL: http://www. medicinescomplete.com/mc/ [Accessed 2008 May 5]
15. Nakamura N. Efficacy of benzbromarone for hyperuricemia [in Japanese]. Rinsho to Kenkyu 1971; 48 (11): 2956-60
16. de Gery A, Auscher C, Saporta L, et al. Treatment of gout and hyperuricaemia by benzbromarone, ethyl 2 (dibromo-3,5 hydroxy-4 benzoyl)-3 benzofuran. Adv Exp Med Biol 1974; 41: 683-9
17. Ravera R. Benzbromarone in the treatment of hyperuricemias [in Italian]. Minerva Med 1975 Mar 7; 66 (17): 783-800
18. Didier M, Olmer M. Hypouricemic effect of benzbromarone especially in kidney failure [in French]. Sem Hop 1978 Apr; 54 (9-12): 463-5
19. Ferber H, Bader U, Matzkies F. The action of benzbromarone in relation to age, sex and accompanying diseases. Adv Exp Med Biol 1980; 122A: 287-94
20. Bluestone R, Klinenberg J, Lee IK. Benzbromarone as a long-term uricosuric agent. Adv Exp Med Biol 1980; 122A: 283-6
21. Scott JT. Comparison of allopurinol and probenecid. Ann Rheum Dis 1966 Nov; 25 (6): 623-6
22. Zurcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994; 9 (5): 548-51
23. Nakamura N. Efficacy of benzbromarone for hyperuricemia: part 2. Comparison with allopurinol [in Japanese]. Rinsho to Kenkyu 1972; 49 (5): 1381-4
24. Mertz DP. The uric acid-lowering action of benzbromarone effervescent granules and allopurinol: comparative studies (author's translation) [in German]. MMW Munch Med Wochenschr 1978 Oct 20; 120 (42): 1387-90
25. Schepers GW. Benzbromarone therapy in hyperuricaemia: comparison with allopurinol and probenecid. J Int Med Res 1981; 9 (6): 511-5
26. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998 Sep; 57 (9): 545-9
27. Perez-Ruiz F, Calabozo M, Fernandez-Lopez M, et al. Treatment of chronic gout in patients with renal function impairment. J Clin Rheumatol 1999; 5 (2): 49-55
28. Hanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai 2002 Jun; 85 Suppl. 1: S40-7
29. Liang L, Xu N, Zhang H, et al. A randomized controlled study of benzbromarone and probenecid in the treatment of gout. West China Medical Journal 1994; 9 (4): 405-8
30. Mertz DP. Reducing the risks in the treatment of gout and hyperuricaemia (author's translation) [in German]. Dtsch Med Wochenschr 1976 Aug 27; 101 (35): 1288-92
31. Frerick H, Schaefer J, Rabinovici K, et al. Longterm treatment of hyperurikemia and gout; randomised study. Therapiewoche 1987; 37 (36): 3379-84
32. Berg H. Effectiveness and tolerance of long-term uricosuric treatment [in German]. Z Gesamte Inn Med 1990 Dec 1; 45 (23): 719-20
33. Akkasilpa S, Osiri M, Deesomchok U, et al. The efficacy of combined low dose of allopurinol and benzbromarone compared to standard dose of allopurinol in hyperuricemia. J Med Assoc Thai 2004 Sep; 87 (9): 1087-91
34. Arntz HR, Dreykluft HR, Leonhardt H. Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study [in German]. Fortschritte der Medizin 1979; 97 (27): 1212-4
35. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10 1999 Oct; (200): 1-203
36. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007 Aug; 3 (8): 443-9
37. Stewart OJ, Silman AJ. Review of UK data on the rheumatic diseases: 4. Gout. Br J Rheumatol 1990 Dec; 29 (6): 485-8
38. Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002 Nov; 29 (11): 2403-6
39. Kim KY, Ralph Schumacher H, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003 Jun; 25 (6): 1593-617
40. Emmerson BT. The management of gout. N Engl J Med 1996 Feb 15; 334 (7): 445-51
41. Gonzalez AA, Puig JG, Mateos FA, et al. Should dietary restrictions always be prescribed in the treatment of gout? Adv Exp Med Biol 1989; 253A: 243-6
42. Ralston SH, Capell HA, Sturrock RD. Alcohol and response to treatment of gout. BMJ (Clin Res Ed) 1988 Jun 11; 296 (6637): 1641-2
43. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout: a systematic review. Rheumatology (Oxford) 2006 Nov; 45 (11): 1422-31
44. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005 May; 17 (3): 319-24
45. Bland JM, Altman DG. Statistics notes: the odds ratio. BMJ 2000 May 27; 320 (7247): 1468
46. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993 Mar; 27 (3): 337-43
47. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995 May; 22 (5): 908-14
48. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006 Oct; 65 (10): 1312-24
49. Day RO, Miners JO, Birkett DJ, et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988 Oct; 26 (4): 423-8
50. Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol 1987 Dec; 26 (6): 445-9
51. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007 Aug; 46 (8): 1372-4
52. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006 Aug; 33 (8): 1646-50
53. Walter-Sack I, de Vries JX, Ernst B, et al. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients: therapeutic equivalence to allopurinol. J Rheumatol 1996 Mar; 23 (3): 498-501
54. Elion GB, Yu TF, Gutman AB, et al. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968 Jul; 45 (1): 69-77
55. Gibson T, Rodgers V, Potter C, et al. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982 Feb; 41 (1): 59-65
56. Tarng DC, Lin HY, Shyong ML, et al. Renal function in gout patients. Am J Nephrol 1995; 15 (1): 31-7
57. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984 Jan; 76 (1): 47-56
58. Walter-Sack I, de Vries JX, Ittensohn A, et al. Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone. Klin Wochenschr 1988 Feb 15; 66 (4): 160-6
59. Jain AK, Ryan JR, McMahon FG, et al. Effect of single oral doses of benzbromarone on serum and urinary uric acid. Arthritis Rheum 1974 Mar-Apr; 17 (2): 149-57
60. Broekhuysen J, Pacco M, Sion R, et al. Metabolism of benzbromarone in man. Eur J Clin Pharmacol 1972 Mar; 4 (2): 125-30
61. Kunishima C, Inoue I, Oikawa T, et al. The metabolism, toxicity and pharmacological studies of benzbromarone (Urinorm). J Saitama Med School 2003; 30 (4): 187-94
62. Uchida S, Shimada K, Misaka S. Influences of CYP2C9 geno-type on pharmacokinetics and pharmacodynamics of benzbromarone [abstract P13. Clin Pharmacol Ther 2006; 79 (2): 13
63. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 2002 Apr; 12 (3): 251-63
64. Walter-Sack I, de Vries JX, von Bubnoff A, et al. Biotrans-formation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis: evidence for active benzbromarone metabolites? Eur J Med Res 1995 Oct 16; 1 (1): 16-20
65. Heel RC, Brogden RN, Speight TM, et al. Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. Drugs 1977; 14: 349-66
66. Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 2007 Mar; 24 (3): 450-70
67. Ichida K, Hosoyamada M, Kimura H, et al. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 2003 Jan; 63 (1): 143-55
68. Sommers DK, Van Wyk M, Moncrieff J, et al. Renal Secretory mechanisms for ampicillin and uric acid. S Afr Med J 1987; 83: 114-5
69. Politta G, Berthoud S, Gaudin G, et al. Mechanism of uricosuric action of benzbromaron [in French]. Schweiz Rundsch Med Prax 1973 Oct 30; 62 (44): 1345-50
70. Kippen I, Nakata N, Honda S, et al. Uptake of uric acid by separated renal tubules of the rabbit. II. Effects of drugs. J Pharmacol Exp Ther 1977 Apr; 201 (1): 226-32
71. Moriwaki Y, Yamamoto T, Takahashi S, et al. Analysis of uric acid transport in renal tubules using benzbromarone and pyrazinamide. Int J Clin Pharmacol Ther Toxicol 1990 Feb; 28 (2): 84-8
72. Kumar S, Ng J, Gow P. Benzbromarone therapy in management of refractory gout. N Z Med J 2005 Jun 24; 118 (1217): U1528
73. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002 Aug; 47 (4): 356-60
74. Masbernard A, Giudicelli CP. Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J 1981 May 9; 59 (20): 701-6
75. Boss GR, Seegmiller JE. Hyperuricemia and gout: classification, complications and management. N Engl J Med 1979 Jun 28; 300 (26): 1459-68
76. Mertz DP, Eichhorn R. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol? Klin Wochenschr 1984 Dec 17; 62 (24): 1170-2
77. Ruffer C, Zorn G, Henkel E, et al. Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol [in German]. Arzneimittelforschung 1982; 32 (9): 1149-52
78. Loffler W, Grobner W, Zollner N. Uric acid-lowering effect of a combination of benzbromarone and allopurinol: studies under standardized dietary conditions [in German]. Arzneimittelforschung 1983; 33 (12): 1687-91
79. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis 1991 Sep; 50 (9): 631-3
80. Bartels EC, Matossian GS. Gout: six-year follow-up on probenecid (benemid) therapy. Arthritis Rheum 1959 Jun; 2 (3): 193-202
81. Thompson GR, Duff IF, Robinson WD, et al. Long term uricosuric therapy in gout. Arthritis Rheum 1962 Aug; 5: 384-96
82. Yue TF, Gutman AB. Effect of allopurinol (4-hydroxypyrazolo(3,4-D) pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 1964 Dec; 37: 885-98
83. Reinders MK, van Roon EN, Houtman PM, et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 2007; 26 (9): 1459-65
84. Stocker SL, Williams KM, McLachlan AJ, et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet 2008; 47 (2): 111-8
85. Wallis RB. Mechanisms of action of sulphinpyrazone. Thromb Res Suppl 1983; 4: 31-8
86. Pedersen AK, FitzGerald GA. The human pharmacology of platelet inhibition: pharmacokinetics relevant to drug action. Circulation 1985 Dec; 72 (6): 1164-76
87. Kersley GD. Allopurinol in primary gout with and after the administration of uricosuric agents. Ann Rheum Dis 1966 Nov; 25 (6 Suppl.): 643-4
88. Tomlinson B. Febuxostat (Teijin/Ipsen/TAP). Curr Opin Investig Drugs 2005 Nov; 6 (11): 1168-78
89. Schumacher HR, Becker Jr MA, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005 Dec 8; 353 (23): 2450-61
90. Kaufmann P, Torok M, Hanni A, et al. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005 Apr; 41 (4): 925-35
91. Bichet N, Cahard D, Fabre G, et al. Toxicological studies on a benzofuran derivative: III. Comparison of peroxisome proliferation in rat and human hepatocytes in primary culture. Toxicol Appl Pharmacol 1990 Dec; 106 (3): 509-17
92. Butler EG, Ichida T, Maruyama H, et al. Toxicological studies on a benzofurane derivative. II. Demonstration of peroxisome proliferation in rat liver. Toxicol Appl Pharmacol 1990 Dec; 106 (3): 500-8
93. Parzefall W, Schuppler J, Barthel G, et al. Toxicological studies on a benzofurane derivative. I. A comparative study with phenobarbital on rat liver. Toxicol Appl Pharmacol 1990 Dec; 106 (3): 482-99
94. Enayetallah AE, French RA, Thibodeau MS, et al. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004; 52 (4): 447-54
95. Takahashi H, Sato T, Shimoyama Y, et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 1999 Dec; 66 (6): 569-81
96. Sevilla-Mantilla C, Ortega L, Agundez JA, et al. Leflunomide induced acute hepatitis. Dig Liver Dis 2004 Jan; 36 (1): 82-4
97. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26 Suppl. 2: 12-21
98. Lilly MB, Omura GA. Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid. Cancer Chemother Pharmacol 1985; 15 (3): 220-2
99. Chaibriant H. Stop marketing of proprietary medical product DESURIC(Rm) (benzbromarone) [online]. Available from URL: http://afssaps.sante.fr/htm/10/ filcoprs/030403.htm [Accessed 2008 May 19]
100. Benzbromarone: withdrawn due to reports of liver damage. WHO Pharmaceuticals Newsletter; 2003: 1
101. Department des alertes [online]. Available from: http://afssaps.sante.fr/ pdf/5/bilan04b.pdf [Accessed 2008 May 19]
102. Masbernard A, Giudicelli CP. Ten years' experience with benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994; 9 (5): 548-51
103. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006 Feb 16; 354 (7): 731-9
104. Department of Economic and Social Affairs United Nations. Population and vital statistics report series A Vol. LIX, No. 1. New York: United Nations; 2007
105. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clinic Proceedings 2006; 81: 925-34
106. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36 (2): 451-5
107. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981 Jun; 40 (3): 245-9
108. Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004 Nov; 71 (6): 481-5
109. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 1996 Dec; 15 (4): 250-7
110. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990 Jan; 126 (1): 43-7
111. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995 Dec 14; 333 (24): 1600-7
112. Chung Y. Utilisation of allopurinol in the Australian community. Intern Med J. In Press
113. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005 Mar 15; 102 (11): 4134-9
114. Myers KW, Katial RK, Engler RJ. Probenecid hypersensitivity in AIDS: a case report. Ann Allergy Asthma Immunol 1998 May; 80 (5): 416-8
115. Izzedine H, Brocheriou I, Becart J, et al. Probenecid-induced membranous nephropathy. Nephrol Dial Transplant 2007 Aug; 22 (8): 2405-6
116. Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 1981 Mar-Apr; 6 (2): 135-51
117. Szczeklik A, Czerniawska-Mysik G, Nizankowska E. Sulfinpyrazone and aspirin-induced asthma. N Engl J Med 1980 Sep 18; 303 (12): 702-3
118. Committee on the Review of Medicines. Recommendations on phenylbutazone, oxyphenbutazone, feprazone, allopurinol, colchicine, probenecid, and sulphinpyrazone. BMJ 1978 Jun 3; 1 (6125): 1466-7
119. Pedersen AK, Jakobsen P, Kampmann JP, et al. Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone. Clin Pharmacokinet 1982 Jan-Feb; 7(1): 42-56
120. Caforio AL, Gambino A, Tona F, et al. Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. J Heart Lung Transplant 2000 Dec; 19 (12): 1205-8
121. Ferrara LA, Mancini M, Marotta T, et al. Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol. Eur J Clin Pharmacol 1986; 29 (6): 717-9
122. Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006 Jan; 33 (1): 104-9